Clinical trials
Chronic Liver Disease clinical trials
Below are recruiting chronic liver disease clinical trials, each written for real people, not researchers. We’re tracking 402 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07530809Recruiting
Time-Restricted Eating for Fatty Liver Disease
This study tests whether eating within a limited time window each day can improve fatty liver disease (a buildup of fat in the liver). If you have moderate-to-advanced fatty liver disease and are overweight, this trial might help you learn if changing when you eat—rather than what you eat—can reduce liver fat and improve your health.
Homburg, SaarlandAges 18–75 - NCT07382349Recruiting
Decision support tools for fatty liver disease
This study tests electronic tools to help doctors identify and care for patients with steatotic liver disease (fatty liver). If you have risk factors like diabetes or elevated liver enzymes, this trial may help improve your care.
Nashville, TennesseeAges 18 years+ - NCT07120464Recruiting
Rabies vaccine study for people with weak immune systems or older age
This study tests how well a rabies vaccine works and how safe it is for people whose immune systems may be weaker, such as those with certain long-term illnesses, organ transplants, or age 60 and older. It compares them to healthy adults ages 18 to 59.
Shenzhen, GuangdongAges Any age - NCT06318169RecruitingPhase 3
Testing pegozafermin for MASH and liver fibrosis
This trial tests an experimental drug called pegozafermin to see if it can help people with MASH (a fatty liver disease) and liver scarring (fibrosis). It's for people who have moderate-to-advanced scarring but not cirrhosis, and who have not had other serious liver conditions or poorly controlled diabetes.
Birmingham, AlabamaAges 18–80 - NCT04634643Recruiting
Studies what causes fatty liver in teens
This study looks at why “nonalcoholic fatty liver disease” happens in teenagers and how it develops. It may help doctors better predict and prevent liver problems in children, even if there isn’t a new drug for you to take.
New Haven, ConnecticutAges 12–18 - NCT03855917RecruitingPhase 4
Short 4-week hepatitis C treatment for early liver disease
This trial tests whether a very short 4-week course of two hepatitis C drugs (sofosbuvir and glecaprevir-pibrentasvir) can cure hepatitis C in people with early-stage liver disease. The goal is to see if a shorter treatment works as well as longer ones.
Darlinghurst, New South WalesAges 18 years+ - NCT07221188RecruitingPhase 3
Efimosfermin alfa for liver scarring in MASH
This study tests an investigational drug called efimosfermin alfa to see if it is safe and tolerable for people who have liver scarring (F2 or F3 stage) from a condition called MASH. The goal is to find out if the drug can help without causing serious side effects.
Arcadia, CaliforniaAges 18–75 - NCT07221227RecruitingPhase 3
Testing a new drug for MASH with moderate scarring
This trial tests a new medicine called Efimosfermin Alfa for people with MASH (a fatty liver disease) and moderate liver scarring. It aims to see if the medicine can improve the liver condition.
Chandler, ArizonaAges 18–75 - NCT03151473Recruiting
Study of adults with fatty liver and NASH over time
This is a long-term study that follows adults who are being managed for fatty liver (NAFL) or NASH to learn how these conditions change over time. It may help researchers better understand what to expect and how care decisions could be improved.
Hong KongAges 18 years+ - NCT03572465Recruiting
Ultrasound tests to diagnose fatty liver inflammation
This study checks whether special ultrasound measurements can help diagnose nonalcoholic steatohepatitis (NASH), a type of fatty liver disease. You may need a liver biopsy as part of routine care, and you may also be scanned with MRI to support the study tests.
Montreal, QuebecAges 18 years+ - NCT03811236Recruiting
Test cold exposure to activate body fat and reduce liver fat
This study tests whether controlled cold exposure can activate “brown fat” and affect liver fat buildup. It may help people with excess liver fat, measured on imaging, but it has several health and medication exclusions.
ViennaAges 18–50 - NCT03920618Recruiting
Testing three HBV medicines for severe liver flare (ACLF)
This study compares three hepatitis B (HBV) medicines to see which treatment helps people with a severe liver flare. You may be eligible if you have confirmed HBV and lab results showing significant liver stress.
Guangzhou, GuangdongAges 12–65 - NCT04496479RecruitingPhase 2
Transplanting donor liver cells near lymph nodes in advanced liver disease
This Phase 2 study tests whether transplanting donor liver cells near lymph nodes can improve outcomes in people with advanced cirrhosis from certain liver conditions. It may help your liver function by adding healthy liver cells, but eligibility is tightly based on your current liver status and other health factors.
Boston, MassachusettsAges 18–70 - NCT04781322RecruitingPhase 1
Study drug to reduce LDL cholesterol effects in heavy drinkers
This Phase 1 study tests how safe a cholesterol-lowering antibody (alirocumab) is in people who drink heavily but are not seeking alcohol treatment. It also looks at early drug effects in the body to see how it might change cholesterol-related signals.
Bethesda, MarylandAges 21–65 - NCT05046483Recruiting
Blood sugar study after a new heart attack
This study measures how your body handles sugar and related hormones in people after a new STEMI heart attack, and compares them with people who do not have diabetes or have prediabetes. The goal is to better understand metabolic changes after the event, which could help future care.
Düsseldorf, North Rhine-WestphaliaAges 18–80 - NCT05178069RecruitingPhase 2
Probiotic supplement study for alcohol use disorder and liver injury
This Phase 2 trial studies whether a probiotic (LGG) can improve health in people with alcohol use disorder and alcohol-related liver injury. It’s not an alcohol treatment study, so participants are mainly joining to see how the supplement affects the body and liver-related outcomes.
Louisville, KentuckyAges 21–65 - NCT05305287RecruitingPhase 4
Study how energy use in the liver works in people with fatty liver and diabetes
This trial measures how your liver cells use energy (mitochondrial function) in people with type 2 diabetes and fatty liver. It aims to better understand what is happening in the liver and how disease severity may relate to diabetes.
San Antonio, TexasAges 18–80 - NCT05385237Recruiting
4D MRI scan to spot liver scarring
This study tests whether a special MRI scan (called 4D-MRI) can identify liver scarring or damage. It may help doctors measure liver fibrosis and inflammation without relying only on invasive tests.
Liestal, Basel-LandschaftAges 18 years+ - NCT05677971RecruitingPhase 3
Tested medicine to treat liver scarring in PiZZ alpha-1 disease
This Phase 3 study tests fazirsiran for safety and whether it can help people with a specific genetic form of alpha-1 antitrypsin–related liver disease that causes liver scarring. You may be eligible if you have the PiZZ genetic type and moderate-to-severe fibrosis, with certain lung and liver conditions ruled out.
Birmingham, AlabamaAges 18–75 - NCT05895890Recruiting
Studying alcohol-related liver disease and addiction care
This study follows adults with alcohol-related liver disease to better understand and manage alcohol addiction and related health problems. You may be able to help researchers by sharing health information and consented care experiences.
Clamart, Île-de-France RegionAges 18–75 - NCT06274788Recruiting
Safety study of long-term Omegaven for liver problems from IV nutrition
This study checks if children who need Omegaven for eight weeks or longer develop a lack of essential fats. It is for kids with liver issues caused by IV nutrition who cannot eat or digest food normally.
Fountain Valley, CaliforniaAges 1 day–17 years - NCT05881005Recruiting
NAC for fatty liver in people with active Cushing’s
This study tests whether NAC (a supplement/medicine) can improve liver health in adults who have active Cushing’s syndrome and fatty liver disease. It may help if your excess stress hormone levels are affecting your liver.
AngersAges 18 years+ - NCT06449833RecruitingPhase 4
Henagliflozin for liver fat in diabetes and fatty liver
This study tests whether a medicine called henagliflozin can help reduce fat in the liver for people with type 2 diabetes and non-alcoholic fatty liver disease. It may help improve liver health and blood sugar control at the same time.
Guangzhou, GuangdongAges 18–75 - NCT06562803Recruiting
Cleaning the blood for liver failure with sepsis
This trial tests if a special blood-filtering method combined with plasma exchange can help people with severe liver failure and sepsis. It aims to reduce inflammation and improve survival.
Guangzhou, GuangdongAges 18–70
Hear when a new Chronic Liver Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for chronic liver disease?
- Yes. Clin2 currently lists 402 recruiting chronic liver disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a chronic liver disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a chronic liver disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.